Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Sort descending Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Eliquis Apixaban Thromboembolic events prevention, (atrial fibrillation) List with clinical criteria and/or conditions Complete
Eliquis Apixaban Venous thromboembolic events, treatment and prevention of recurrence List with clinical criteria and/or conditions Complete
Kynmobi apomorphine hydrochloride Parkinson’s disease Reimburse with clinical criteria and/or conditions Complete
Movapo apomorphine hydrochloride Parkinson's disease Reimburse with clinical criteria and/or conditions Complete
Kynmobi apomorphine hydrochloride Parkinson’s Disease Withdrawn
Otezla Apremilast Arthritis, psoriatic List with criteria/condition Complete
Otezla Apremilast Plaque psoriasis Do not list Complete
Otezla Apremilast Psoriasis, moderate to severe plaque Reimburse with clinical criteria and/or conditions Complete
Emend Aprepitant Nausea and Vomiting, Chemotherapy induced List with clinical criteria and/or conditions Complete
Abilify Aripiprazole Schizophrenia Do not list Complete